## Sikhulile Moyo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9010540/publications.pdf

Version: 2024-02-01

170 papers 12,190 citations

136740 32 h-index 28224 105 g-index

176 all docs

176 docs citations

176 times ranked

12580 citing authors

#	Article	IF	CITATIONS
1	Prevention of HIV-1 Infection with Early Antiretroviral Therapy. New England Journal of Medicine, 2011, 365, 493-505.	13.9	6,046
2	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603, 679-686.	13.7	1,210
3	Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. New England Journal of Medicine, 2010, 362, 427-439.	13.9	476
4	Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana. New England Journal of Medicine, 2010, 362, 2282-2294.	13.9	462
5	Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 658-665.	0.6	413
6	Increased Risk of Preterm Delivery Among HIV-Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor-Based HAART During Pregnancy. Journal of Infectious Diseases, 2011, 204, 506-514.	1.9	207
7	Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV,the, 2016, 3, e221-e230.	2.1	197
8	Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. New England Journal of Medicine, 2019, 381, 230-242.	13.9	163
9	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	6.0	144
10	Length of secondary schooling and risk of HIV infection in Botswana: evidence from a natural experiment. The Lancet Global Health, 2015, 3, e470-e477.	2.9	104
11	Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet, The, 2021, 397, 1276-1292.	6.3	82
12	Optimising growth conditions for the pectinolytic activity of Kluyveromyces wickerhamii by using response surface methodology. International Journal of Food Microbiology, 2003, 85, 87-100.	2.1	76
13	Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 318-322.	0.9	75
14	Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Science Translational Medicine, 2019, 11, .	5.8	74
15	Impact of Sampling Density on the Extent of HIV Clustering. AIDS Research and Human Retroviruses, 2014, 30, 1226-1235.	0.5	71
16	Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable. Journal of Clinical Microbiology, 2016, 54, 3050-3055.	1.8	67
17	The Reverse Transcriptase 67N 70R 215Y Genotype Is the Predominant TAM Pathway Associated with Virologic Failure among HIV Type 1C-Infected Adults Treated with ZDV/ddl-Containing HAART in Southern Africa. AIDS Research and Human Retroviruses, 2007, 23, 868-878.	0.5	65
18	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 0, , .	13.7	61

#	Article	IF	Citations
19	Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 112-116.	0.9	54
20	Increased Risk of Severe Infant Anemia After Exposure to Maternal HAART, Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 428-436.	0.9	53
21	Response to Zidovudine/Didanosine-Containing Combination Antiretroviral Therapy Among HIV-1 Subtype C-Infected Adults in Botswana: Two-Year Outcomes from a Randomized Clinical Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 37-46.	0.9	51
22	Transmission of Single and Multiple Viral Variants in Primary HIV-1 Subtype C Infection. PLoS ONE, 2011, 6, e16714.	1.1	47
23	An early warning system for emerging SARS-CoV-2 variants. Nature Medicine, 2022, 28, 1110-1115.	15.2	47
24	Serological Evidence of HIV-Associated Infection among HIV-1-Infected Adults in Botswana. Clinical Infectious Diseases, 2006, 43, 1612-1615.	2.9	46
25	HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the "Test-and-Treat―Approach to Reduce HIV Transmission. PLoS ONE, 2010, 5, e10148.	1.1	46
26	HIV-1 subtype C in vitro growth and coreceptor utilization. Virology, 2006, 347, 247-260.	1,1	45
27	Unintended pregnancy, contraceptive use, and childbearing desires among HIV-infected and HIV-uninfected women in Botswana: across-sectional study. BMC Public Health, 2015, 16, 44.	1.2	40
28	Viral Load and CD4+ T-Cell Dynamics in Primary HIV-1 Subtype C Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 65-76.	0.9	39
29	Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu) Tj ETQq1 1 e491-e500.	0.784314 2.9	rgBT /Over 39
30	Old plants newly discovered: Cassia sieberiana D.C. and Cassia abbreviata Oliv. Oliv. root extracts inhibit in vitro HIV-1c replication in peripheral blood mononuclear cells (PBMCs) by different modes of action. Journal of Ethnopharmacology, 2012, 141, 48-56.	2.0	36
31	Persistently Elevated Serum Interleukin-6 Predicts Mortality Among Adults Receiving Combination Antiretroviral Therapy in Botswana: Results from a Clinical Trial. AIDS Research and Human Retroviruses, 2013, 29, 993-999.	0.5	36
32	HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana. Aids, 2013, 27, 1911-1920.	1.0	36
33	Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. Aids, 2010, 24, S27-S36.	1.0	35
34	HIV-exposed children account for more than half of 24-month mortality in Botswana. BMC Pediatrics, 2016, 16, 103.	0.7	35
35	Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology, 2009, 383, 47-59.	1.1	34
36	An Augmented SMS Intervention to Improve Access to Antenatal CD4 Testing and ART Initiation in HIV-Infected Pregnant Women: A Cluster Randomized Trial. PLoS ONE, 2015, 10, e0117181.	1.1	34

3

#	Article	IF	Citations
37	Phylogenetic Relatedness of Circulating HIV-1C Variants in Mochudi, Botswana. PLoS ONE, 2013, 8, e80589.	1.1	33
38	Intra-host evolutionary rates in HIV-1C env and gag during primary infection. Infection, Genetics and Evolution, 2013, 19, 361-368.	1.0	31
39	High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open Forum Infectious Diseases, 2017, 4, ofx195.	0.4	31
40	Better Control of Early Viral Replication Is Associated With Slower Rate of Elicited Antiviral Antibodies in the Detuned Enzyme Immunoassay During Primary HIV-1C Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 265-272.	0.9	29
41	Prevalence of human papillomavirus genotypes and associated cervical squamous intraepithelial lesions in HIVâ€infected women in Botswana. Journal of Medical Virology, 2011, 83, 1689-1695.	2.5	29
42	Estimated age and gender profile of individuals missed by a homeâ€based HIV testing and counselling campaign in a Botswana community. Journal of the International AIDS Society, 2015, 18, 19918.	1.2	29
43	Implementation of the World Health Organization Regional Office for Africa Stepwise Laboratory Quality Improvement Process Towards Accreditation. African Journal of Laboratory Medicine, 2016, 5, 280.	0.2	29
44	Timing Constraints of In Vivo Gag Mutations during Primary HIV-1 Subtype C Infection. PLoS ONE, 2009, 4, e7727.	1.1	27
45	High Viral Load and Elevated Angiogenic Markers Associated With Increased Risk of Preeclampsia Among Women Initiating Highly Active Antiretroviral Therapy in Pregnancy in the Mma Bana Study, Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 517-524.	0.9	27
46	Identifying Recent HIV Infections: From Serological Assays to Genomics. Viruses, 2015, 7, 5508-5524.	1.5	27
47	HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana. Cardiovascular Journal of Africa, 2018, 29, 155-161.	0.2	26
48	Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana. Open Forum Infectious Diseases, 2016, 3, of w140.	0.4	25
49	Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering. Journal of Clinical Microbiology, 2015, 53, 2581-2592.	1.8	24
50	Brief Report: High Sensitivity and Specificity of the Cepheid Xpert HIV-1 Qualitative Point-of-Care Test Among Newborns in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e128-e131.	0.9	24
51	Phylodynamic analysis of HIV sub-epidemics in Mochudi, Botswana. Epidemics, 2015, 13, 44-55.	1.5	22
52	Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine, 2016, 8, 237-247.	2.7	22
53	Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana. Aids, 2018, 32, 1899-1902.	1.0	22
54	Prevalence of Transmitted HIV Drug Resistance in Botswana: Lessons Learned from the HIVDR-Threshold Survey Conducted Among Women Presenting for Routine Antenatal Care as Part of the 2007 National Sentinel Survey. AIDS Research and Human Retroviruses, 2011, 27, 365-372.	0.5	21

#	Article	IF	Citations
55	Chronic and Occult Hepatitis B Virus Infection in Pregnant Women in Botswana. Genes, 2018, 9, 259.	1.0	21
56	Acceptability of oral HIV self-testing among female sex workers in Gaborone, Botswana. PLoS ONE, 2020, 15, e0236052.	1.1	21
57	Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology, 2012, 433, 296-307.	1.1	20
58	Cotrimoxazole prophylaxis was associated with enteric commensal bacterial resistance among HIVâ€exposed infants in a randomized controlled trial, Botswana. Journal of the International AIDS Society, 2017, 20, e25021.	1.2	20
59	Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015. PLoS ONE, 2018, 13, e0204840.	1.1	20
60	Molecular detection of human papillomavirus (HPV) in highly fragmented DNA from cervical cancer biopsies using double-nested PCR. MethodsX, 2018, 5, 569-578.	0.7	20
61	Dynamics and timing of in vivo mutations at Gag residue 242 during primary HIV-1 subtype C infection. Virology, 2010, 403, 37-46.	1.1	19
62	Genetic and epidemiological analysis of norovirus from children with gastroenteritis in Botswana, 2013–2015. BMC Infectious Diseases, 2018, 18, 246.	1.3	19
63	Highly Active Antiretroviral Therapy Versus Zidovudine for Prevention of Mother-to-Child Transmission in a Programmatic Setting, Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 353-357.	0.9	18
64	HIV-1 Full-Genome Phylogenetics of Generalized Epidemics in Sub-Saharan Africa: Impact of Missing Nucleotide Characters in Next-Generation Sequences. AIDS Research and Human Retroviruses, 2017, 33, 1083-1098.	0.5	18
65	Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: A decentralization pilot study. Journal of Virological Methods, 2009, 159, 93-97.	1.0	17
66	Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering. AIDS Research and Human Retroviruses, 2015, 31, 531-542.	0.5	17
67	The effect of micronutrient supplementation on active TB incidence early in HIV infection in Botswana. Nutrition and Dietary Supplements, 2017, Volume 9, 37-45.	0.7	17
68	Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial. Lancet HIV,the, 2020, 7, e422-e433.	2.1	17
69	Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clinical Infectious Diseases, 2021, 72, 388-393.	2.9	17
70	Prevalence and Clinical Associations of CXCR4-Using HIV-1 Among Treatment-Naive Subtype C-Infected Women in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 46-50.	0.9	16
71	Molecular characterisation of hepatitis B virus in HIV-1 subtype C infected patients in Botswana. BMC Infectious Diseases, 2015, 15, 335.	1.3	16
72	HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana. Viruses, 2021, 13, 594.	1.5	15

#	Article	IF	CITATIONS
73	Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls. PLoS ONE, 2017, 12, e0179994.	1.1	15
74	Immunohaematological reference values for HIV-negative healthy adults in Botswana. African Journal of Laboratory Medicine, $2011,1,.$	0.2	15
75	Evaluation of the False Recent Classification Rates of Multiassay Algorithms in Estimating HIV Type 1 Subtype C Incidence. AIDS Research and Human Retroviruses, 2014, 30, 29-36.	0.5	14
76	Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana. PLoS ONE, 2016, 11, e0160649.	1.1	14
77	Targeted HIV testing at birth supported by low and predictable motherâ€toâ€child transmission risk in Botswana. Journal of the International AIDS Society, 2018, 21, e25111.	1.2	14
78	Undisclosed antiretroviral drug use in Botswana. Aids, 2018, 32, 1543-1546.	1.0	14
79	Brief Report: High Rates of Adverse Birth Outcomes in HIV and Syphilis Coinfected Women in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e135-e140.	0.9	14
80	Molecular characterization of hepatitis B virus in blood donors in Botswana. Virus Genes, 2019, 55, 33-42.	0.7	14
81	Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana. International Journal of Cancer, 2020, 146, 1667-1673.	2.3	14
82	Training-of-trainers: A strategy to build country capacity for SLMTA expansion and sustainability. African Journal of Laboratory Medicine, 2014, 3, 196.	0.2	13
83	Therapeutic Levels of Lopinavir in Late Pregnancy and Abacavir Passage into Breast Milk in the Mma Bana Study, Botswana. Antiviral Therapy, 2013, 18, 1-6.	0.6	12
84	Effect of BMI and fat mass on HIV disease progression in HIV-infected, antiretroviral treatment-na $\tilde{A}$ -ve adults in Botswana. British Journal of Nutrition, 2016, 115, 2114-2121.	1.2	12
85	Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 235-241.	0.9	12
86	Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial. Journal of Infectious Diseases, 2020, 222, 1670-1680.	1.9	12
87	Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial $\hat{a} \in BCPP/Ya$ Tsie trial. ELife, 2022, 11, .	2.8	12
88	Deciphering Multiplicity of HIV-1C Infection: Transmission of Closely Related Multiple Viral Lineages. PLoS ONE, 2016, 11, e0166746.	1.1	11
89	The Impact of Human Pegivirus on CD4 Cell Count in HIV-Positive Persons in Botswana. Open Forum Infectious Diseases, 2017, 4, ofx222.	0.4	11
90	Prevalence of oncogenic human papillomavirus genotypes in patients diagnosed with anogenital malignancies in Botswana. BMC Infectious Diseases, 2017, 17, 731.	1.3	11

#	Article	IF	Citations
91	B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine. Frontiers in Immunology, 2018, 8, 2002.	2.2	11
92	Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. AIDS Research and Human Retroviruses, 2018, 34, 667-671.	0.5	11
93	Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana. PLoS ONE, 2018, 13, e0192030.	1.1	11
94	Lack of Virological Suppression Among Young HIV-Positive Adults in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 557-565.	0.9	11
95	Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana. Aids, 2019, 33, 1073-1082.	1.0	11
96	Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clinical Infectious Diseases, 2021, 73, e997-e1003.	2.9	11
97	Molecular Characterization of Near Full-Length Genomes of Hepatitis B Virus Isolated from Predominantly HIV Infected Individuals in Botswana. Genes, 2018, 9, 453.	1.0	10
98	Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay. PLoS ONE, 2019, 14, e0211260.	1.1	10
99	Translating a National Laboratory Strategic Plan into action through SLMTA in a district hospital laboratory in Botswana. African Journal of Laboratory Medicine, 2014, 3, 209.	0.2	10
100	Progressing beyond SLMTA: Are internal audits and corrective action the key drivers of quality improvement?. African Journal of Laboratory Medicine, 2014, 3, 222.	0.2	10
101	HIV-1 drug mutations in children from northern Tanzania. Journal of Antimicrobial Chemotherapy, 2014, 69, 1928-1932.	1.3	9
102	Prognostic Value of HIV-1 RNA on CD4 Trajectories and Disease Progression Among Antiretroviral-Naive HIV-Infected Adults in Botswana: A Joint Modeling Analysis. AIDS Research and Human Retroviruses, 2016, 32, 573-578.	0.5	9
103	Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana. Pathogens, 2019, 8, 208.	1.2	9
104	Genetic diversity of Mycobacterium tuberculosis strains circulating in Botswana. PLoS ONE, 2019, 14, e0216306.	1.1	9
105	Comparison of an in-house †home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples. PLoS ONE, 2019, 14, e0224292.	1.1	9
106	HIV Exposure and Formula Feeding Predict Under-2 Mortality in HIV-Uninfected Children, Botswana. Journal of Pediatrics, 2018, 203, 68-75.e2.	0.9	8
107	Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 335-347.	0.4	8
108	Infant Feeding Practices were not Associated with Breast Milk HIV-1 RNA Levels in a Randomized Clinical Trial in Botswana. AIDS and Behavior, 2012, 16, 1260-1264.	1.4	7

7

#	Article	IF	CITATIONS
109	Predictors of early breastfeeding cessation among <scp>HIV</scp> â€infected women in Botswana. Tropical Medicine and International Health, 2016, 21, 1013-1018.	1.0	7
110	Human Immunodeficiency Virus Exposure but Not Early Cytomegalovirus Infection Is Associated With Increased Hospitalization and Decreased Memory T-Cell Responses to Tetanus Vaccine. Journal of Infectious Diseases, 2020, 221, 1167-1175.	1.9	7
111	HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana. Journal of Antimicrobial Chemotherapy, 2022, 77, 1385-1395.	1.3	7
112	Temporal Reduction of HIV Type 1 Viral Load in Breast Milk by Single-Dose Nevirapine during Prevention of MTCT. AIDS Research and Human Retroviruses, 2009, 25, 1261-1264.	0.5	6
113	Vitamin D Insufficiency in HIV-infected Pregnant Women Receiving Antiretroviral Therapy is Not Associated With Morbidity, Mortality or Growth Impairment in Their Uninfected Infants in Botswana. Pediatric Infectious Disease Journal, 2014, 33, 1141-1147.	1.1	6
114	Immune Phenotype and Functionality of Mtb-Specific T-Cells in HIV/TB Co-Infected Patients on Antiretroviral Treatment. Pathogens, 2020, 9, 180.	1.2	6
115	In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana. Viruses, 2020, 12, 731.	1.5	6
116	Promoter Hypermethylation Analysis of Host Genes in Cervical Cancer Patients With and Without Human Immunodeficiency Virus in Botswana. Frontiers in Oncology, 2021, 11, 560296.	1.3	6
117	Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. Aids, 2021, 35, 2413-2421.	1.0	6
118	No Clinically Significant Drug-Resistance Mutations in HIV-1 Subtype C–Infected Women After Discontinuation of NRTI-Based or PI-Based HAART for PMTCT in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 572-577.	0.9	5
119	Immune Activation Markers in Peripartum Women in Botswana: Association with Feeding Strategy and Maternal Morbidity. PLoS ONE, 2014, 9, e89928.	1.1	5
120	Plasma Cytokine Levels in Chronic Asymptomatic HIV-1 Subtype C Infection as an Indicator of Disease Progression in Botswana: A Retrospective Case Control Study. AIDS Research and Human Retroviruses, 2016, 32, 364-369.	0.5	5
121	In Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel Algorithm. Genes, 2018, 9, 420.	1.0	5
122	Hepatitis B virus prevalence and vaccine antibody titers in children HIV exposed but uninfected in Botswana. PLoS ONE, 2020, 15, e0237252.	1.1	5
123	Human Immunodeficiency Virus (HIV) Genetic Diversity Informs Stage of HIV-1 Infection Among Patients Receiving Antiretroviral Therapy in Botswana. Journal of Infectious Diseases, 2022, 225, 1330-1338.	1.9	5
124	Genetic diversity in L1 ORF of human papillomavirus in women with cervical cancer with and without human immunodeficiency virus in Botswana and Kenya. BMC Infectious Diseases, 2022, 22, 95.	1.3	5
125	Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women. Journal of the International AIDS Society, 2012, 15, 17393.	1.2	4
126	Short Communication: Low False Recent Rate of Limiting Antigen-Avidity Assay Combined with HIV-1 RNA Data in Botswana. AIDS Research and Human Retroviruses, 2017, 33, 17-18.	0.5	4

#	Article	IF	CITATIONS
127	Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study. BMC Infectious Diseases, 2019, 19, 875.	1.3	4
128	High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National antiretroviral therapy programme between 2011 and 2015. Aids, 2019, 33, 2415-2422.	1.0	4
129	Incidence of hepatitis B virus infection among human immunodeficiency virus-infected treatment $na\tilde{A}^{-}ve$ adults in Botswana. Medicine (United States), 2020, 99, e19341.	0.4	4
130	Next generation sequencing of near-full length genome of norovirus GII.4 from Botswana. Virus Research, 2021, 302, 198491.	1.1	4
131	Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In Botswana. Journal of Antivirals & Antiretrovirals, 2011, 03, 45-48.	0.1	4
132	Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-na $\tilde{A}$ -ve HIV-1 Subtype C-infected patients in Botswana. AAS Open Research, 2020, 3, 50.	1.5	4
133	Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection. Virology, 2011, 421, 119-128.	1.1	3
134	Pairwise diversity and tMRCA as potential markers for HIV infection recency. Medicine (United States), 2017, 96, e6041.	0.4	3
135	Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana. Biomedicines, 2022, 10, 1399.	1.4	3
136	High HIV-1 RNA Among Newly Diagnosed People in Botswana. AIDS Research and Human Retroviruses, 2018, 34, 300-306.	0.5	2
137	HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. Viruses, 2020, 12, 1404.	1.5	2
138	HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life. Aids, 2020, 34, 1029-1035.	1.0	2
139	Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-na $\tilde{A}$ -ve HIV-1 Subtype C-infected patients in Botswana. AAS Open Research, 2020, 3, 50.	1.5	2
140	Limited HIV-1 Subtype C nef $3\hat{a}\in^2$ PPT Variation in Combination Antiretroviral Therapy Na $\tilde{A}$ -ve and Experienced People Living with HIV in Botswana. Pathogens, 2021, 10, 1027.	1.2	2
141	Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana. Southern African Journal of HIV Medicine, 2018, 19, 751.	0.3	2
142	Feasibility of oral HIV self-testing in female sex workers in Gaborone, Botswana. PLoS ONE, 2021, 16, e0259508.	1.1	2
143	Short Communication: Effect of Short-Course Antenatal Zidovudine and Single-Dose Nevirapine on the BED Capture Enzyme Immunoassay Levels in HIV Type 1 Subtype C Infection. AIDS Research and Human Retroviruses, 2013, 29, 901-906.	0.5	1
144	Prevalence and molecular characterization of Hepatitis B in HIV infected individuals in Botswana. BMC Infectious Diseases, 2014, 14, .	1.3	1

#	Article	IF	CITATIONS
145	Secondary education and HIV infection in Botswana. The Lancet Global Health, 2016, 4, e23.	2.9	1
146	No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed Infants in Botswana. Open Forum Infectious Diseases, 2017, 4, S665-S665.	0.4	1
147	Cytomegalovirus Viremia in HIV-1 Subtype C Positive Women at Delivery in Botswana and Adverse Birth/Infant Health Outcomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 118-124.	0.9	1
148	Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination. Medicine (United States), 2019, 98, e18014.	0.4	1
149	Child HIV Exposure and CMV Seroprevalence in Botswana: No Associations With 24-Month Growth and Neurodevelopment. Open Forum Infectious Diseases, 2020, 7, ofaa373.	0.4	1
150	Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana. AIDS Research and Human Retroviruses, 2021, 37, 16-23.	0.5	1
151	Decreased HBV vaccine response among HIV positive infants compared to HIV negative infants in Botswana. Aids, 2022, Publish Ahead of Print, .	1.0	1
152	Impact of pre-COVID-19 epidemic preparedness on the trajectory of the pandemic in African countries. African Journal of Laboratory Medicine, 2022, 11, 1571.	0.2	1
153	Increased Risk of Preterm Delivery Among HIV-Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor–Based HAART During Pregnancy. Obstetrical and Gynecological Survey, 2011, 66, 751-753.	0.2	0
154	Increased Prevalence of Liver Fibrosis and HIV Viremia among Patients with HIV, HBV, and Tuberculosis in Botswana. Pathogens, 2020, 9, 950.	1.2	0
155	Efficient estimation of human immunodeficiency virus incidence rate using a pooled crossâ€sectional cohort study design. Statistics in Medicine, 2020, 39, 3255-3271.	0.8	0
156	Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study. Southern African Journal of Infectious Diseases, 2021, 36, .	0.3	0
157	Lack of HIV RNA test result is a barrier to breastfeeding among women living with HIV in Botswana. International Breastfeeding Journal, 2021, 16, 81.	0.9	O
158	Lack of RH2 gene expression may have influenced the HIV pandemic in sub-Saharan Africa. Aids, 2021, 35, 769-776.	1.0	0
159	Maternal Hepatitis B Virus Infection, Pregnancy, and Infant Health Outcomes in Botswana. Hepatitis Monthly, 2019, 19, .	0.1	0
160	Title is missing!. , 2019, 14, e0224292.		0
161	Title is missing!. , 2019, 14, e0224292.		0
162	Title is missing!. , 2019, 14, e0224292.		0

#	Article	IF	CITATIONS
163	Title is missing!. , 2019, 14, e0224292.		O
164	Title is missing!. , 2020, 15, e0237252.		0
165	Title is missing!. , 2020, 15, e0237252.		0
166	Title is missing!. , 2020, 15, e0237252.		0
167	Title is missing!. , 2020, 15, e0237252.		O
168	Title is missing!. , 2020, 15, e0237252.		0
169	Title is missing!. , 2020, 15, e0237252.		O
170	The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes. Medicine (United States), 2022, 101, e29066.	0.4	0